fluorodeoxyglucose f18 has been researched along with Cancer of the Urinary Tract in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (25.00) | 29.6817 |
| 2010's | 14 (70.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, J; Ding, L; Li, N; Meng, X; Sheng, X; Wang, F; Wang, S; Yang, Z; Yao, S; Zhang, Y; Zhu, H | 1 |
| Hotta, M; Minamimoto, R; Suzuki, D; Takahashi, A | 1 |
| Bouchelouche, K; Dias, AH; Ipsen, P | 1 |
| Lin, M; Lin, P; Naik, N | 1 |
| Bal, A; Bhattacharya, A; Kumar, R; Mittal, BR; Prakash, G; Singh, H; Vadi, SK | 1 |
| Asai, S; Fukumoto, T; Kikugawa, T; Koyama, K; Miura, N; Miyagawa, M; Miyauchi, Y; Noda, T; Saika, T; Sawada, Y; Watanabe, R; Yanagihara, Y | 1 |
| Fujii, Y; Fukushima, H; Ishioka, J; Ito, M; Kihara, K; Kobayashi, M; Koga, F; Matsuoka, Y; Numao, N; Saito, K; Tanaka, H; Tateishi, U; Uehara, S; Yokoyama, M; Yonese, J; Yoshida, S | 1 |
| Fanti, S; Nanni, C; Zanoni, L | 1 |
| Adshead, JM; Ali, T; Boustead, G; Haslam, P; Lane, T; Mafeld, S; Patel, A; Thorpe, AC; Vasdev, N | 1 |
| Asai, S; Fukumoto, T; Kikugawa, T; Miura, N; Miyagawa, M; Miyauchi, Y; Nishimura, K; Shirato, A; Tanji, N; Yanagihara, Y; Yokoyama, M | 1 |
| Hess, S; Høilund-Carlsen, PF; Lund, L; Petersen, H; Poulsen, MH | 1 |
| Fukushima, K; Hirota, S; Igarashi, Y; Katsuura, T; Kawanaka, Y; Kitajima, K; Mouri, M; Yamakado, K; Yamamoto, S | 1 |
| Fukushima, K; Jadvar, H; Kamai, T; Kitajima, K; Minamimoto, R; Yamamoto, S | 1 |
| Labarthe, P; Lebret, T; Méjean, A | 1 |
| Chang, CH; Ding, HJ; Hsieh, TC; Kao, CH; Sun, SS; Wu, HC | 1 |
| Avril, N; Dambha, F; Murray, I; Powles, T; Sahdev, A; Shamash, J | 1 |
| Han, A; Hu, M; Wang, X; Xue, J; Zheng, J | 1 |
| Bourguet, P | 1 |
| Boerner, AR; Hofmann, M; Jonas, U; Knapp, WH; Machtens, S | 1 |
| Henderson, R; Ho, L; Quan, V; Seto, J | 1 |
7 review(s) available for fluorodeoxyglucose f18 and Cancer of the Urinary Tract
| Article | Year |
|---|---|
Nuclear medicine in urological cancers: what is new?
Topics: Fluorodeoxyglucose F18; Humans; Nuclear Medicine; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Urologic Neoplasms | 2014 |
Evolving role of positron emission tomography (PET) in urological malignancy.
Topics: Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Positron-Emission Tomography; Urologic Neoplasms | 2015 |
FDG in Urologic Malignancies.
Topics: Fluorodeoxyglucose F18; Humans; Kidney Neoplasms; Male; Multimodal Imaging; Neoplasm Metastasis; Neoplasm Staging; Positron-Emission Tomography; Prostatic Neoplasms; Radiopharmaceuticals; Tomography, X-Ray Computed; Urinary Bladder Neoplasms; Urologic Neoplasms | 2014 |
Update on advances in molecular PET in urological oncology.
Topics: Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Male; Multimodal Imaging; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Urinary Tract; Urologic Neoplasms | 2016 |
The clinical advances of fluorine-2-D-deoxyglucose--positron emission tomography/computed tomography in urological cancers.
Topics: Carcinoma, Renal Cell; Fluorodeoxyglucose F18; Humans; Kidney Neoplasms; Male; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Prostatic Neoplasms; Radiopharmaceuticals; Tomography, X-Ray Computed; Urinary Bladder Neoplasms; Urologic Neoplasms | 2010 |
[Standards, Options and Recommendations for the use of PET-FDG in cancerology. Results in urological cancers].
Topics: Bone Neoplasms; Fluorodeoxyglucose F18; Humans; Kidney Neoplasms; Male; Neoplasm Recurrence, Local; Prostatic Neoplasms; Radiopharmaceuticals; Seminoma; Testicular Neoplasms; Tomography, Emission-Computed; Urinary Bladder Neoplasms; Urologic Neoplasms | 2003 |
[Positron emission tomography (PET) for diagnosis and monitoring of treatment for urological tumors].
Topics: Algorithms; Fluorodeoxyglucose F18; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Imaging, Three-Dimensional; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Urogenital Neoplasms; Urologic Neoplasms; Urology | 2004 |
13 other study(ies) available for fluorodeoxyglucose f18 and Cancer of the Urinary Tract
| Article | Year |
|---|---|
Positron Emission Tomography Imaging of Programmed Death 1 Expression in Cancer Patients Using 124I-Labeled Toripalimab: A Pilot Clinical Translation Study.
Topics: Adult; Antibodies, Monoclonal, Humanized; Female; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Humans; Iodine Radioisotopes; Isotope Labeling; Male; Melanoma; Middle Aged; Pilot Projects; Positron Emission Tomography Computed Tomography; Programmed Cell Death 1 Receptor; Radiometry; Tissue Distribution; Translational Research, Biomedical; Urologic Neoplasms | 2021 |
Multicentric Reticulohistiocytosis Mimicking Malignancy on 18F-FDG PET/CT.
Topics: Aged; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Histiocytosis; Humans; Positron Emission Tomography Computed Tomography; Recurrence; Urologic Neoplasms; Urothelium | 2017 |
Incidental Diagnosis of a Large Retroperitoneal Urine Accumulation (Urinoma) on an 18F-FDG PET/CT Scan Performed for Primary Staging of Urothelial Carcinoma.
Topics: Fluorodeoxyglucose F18; Humans; Incidental Findings; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Urinoma; Urologic Neoplasms | 2017 |
Genitourinary involvement of lymphomas on FDG-PET.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Genital Neoplasms, Female; Genital Neoplasms, Male; Humans; Kidney Neoplasms; Lymphoma; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Ureteral Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms | 2018 |
Incidental Detection of an Unusual Case of B-Cell Lymphoma of the Urachal Remnant on 18F-FDG PET/CT.
Topics: Adult; Female; Fluorodeoxyglucose F18; Humans; Lymphoma, B-Cell; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Urachus; Urologic Neoplasms | 2018 |
New classification of hydronephrosis on 18F-FDG-PET/CT predicts post-operative renal function and muscle-invasive disease in patients with upper urinary tract urothelial carcinoma.
Topics: Aged; Aged, 80 and over; Cisplatin; Female; Fluorodeoxyglucose F18; Glomerular Filtration Rate; Humans; Hydronephrosis; Kidney; Male; Middle Aged; Multivariate Analysis; Nephrectomy; Nephroureterectomy; Positron Emission Tomography Computed Tomography; Postoperative Period; Retrospective Studies; Treatment Outcome; Ureter; Urologic Neoplasms; Urothelium | 2018 |
Impact of fluorodeoxyglucose uptake on positron emission tomography/computed tomography on chemosensitivity and survival in patients with metastatic urothelial carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Drug Resistance, Neoplasm; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Progression-Free Survival; Radiopharmaceuticals; Urologic Neoplasms | 2019 |
Fluorodeoxyglucose positron emission tomography/computed tomography for diagnosis of upper urinary tract urothelial carcinoma.
Topics: Aged; Aged, 80 and over; Biopsy; Carcinoma, Transitional Cell; Cytodiagnosis; Female; Fluorodeoxyglucose F18; Humans; Hysteroscopy; Kidney Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed; Ureteral Neoplasms; Urinalysis; Urologic Neoplasms | 2015 |
FDG-PET/CT as a post-treatment restaging tool in urothelial carcinoma: Comparison with contrast-enhanced CT.
Topics: Adult; Aged; Aged, 80 and over; Contrast Media; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Neoplasm Recurrence, Local; Neoplasm Staging; Positron-Emission Tomography; Radiographic Image Enhancement; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome; Urologic Neoplasms; Urothelium | 2016 |
[PET-FDG in metastases from urological malignancies].
Topics: Fluorodeoxyglucose F18; Humans; Neoplasm Metastasis; Positron-Emission Tomography; Radiopharmaceuticals; Urologic Neoplasms | 2008 |
Preliminary study of detecting urothelial malignancy with FDG PET in Taiwanese ESRD patients.
Topics: Female; Fluorodeoxyglucose F18; Humans; Kidney Failure, Chronic; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Tomography, X-Ray Computed; Urologic Neoplasms | 2009 |
Clinical value of 18F-FDG PET-CT in detecting primary tumor for patients with carcinoma of unknown primary.
Topics: Adult; Aged; Breast Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Digestive System Neoplasms; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Hemangiosarcoma; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Neoplasms, Unknown Primary; Ovarian Neoplasms; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Prostatic Neoplasms; Retrospective Studies; Sensitivity and Specificity; Stomach Neoplasms; Tomography, X-Ray Computed; Urologic Neoplasms | 2012 |
High-grade urothelial carcinoma of the prostate on FDG PET-CT.
Topics: Aged; Fluorodeoxyglucose F18; Humans; Male; Positron-Emission Tomography; Prostatic Neoplasms; Radiopharmaceuticals; Subtraction Technique; Tomography, X-Ray Computed; Urologic Neoplasms; Urothelium | 2007 |